A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Subjects with Active Psoriatic Arthritis Axial Disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504716-15-00

Acronym

CNTO1959PSA4002

Enrollment

236

Registered

2024-05-02

Start date

2021-08-06

Completion date

Unknown

Last updated

2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Brief summary

Change from baseline in BASDAI at Week 24.

Interventions

DRUGGuselkumab 1 mL PFS Placebo

DRUGGuselkumab - solution for injection in pre-filled syringe - 100 mg/mL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in BASDAI at Week 24.	—

Countries

Bulgaria, Czechia, Denmark, Germany, Hungary, Italy, Poland, Portugal, Slovakia, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026